---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-26-000024"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2026-04-08T23:59:59+00:00"
generated_at: "2026-05-15T06:53:25.395131+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nurix Q1 net loss $87.2M ($0.79); advancing bexobrutideg registrational program

## Summary
- Revenue $6.3M vs $18.5M YoY; net loss $87.2M ($0.79) vs $56.4M ($0.67).
- Cash $540.7M vs $592.9M at Nov 30, 2025; net burn ~$52M in quarter.
- Enrolling Phase 2 DAYBreak CLL-201 for bexobrutideg; Phase 3 confirmatory trial planned mid-2026.
- Healthy volunteer SAD/MAD study of new tablet formulation to support IND in immunology/inflammation.
- Sanofi advancing STAT6 degrader NX-3911; Gilead advancing IRAK4 degrader GS-6791 in Phase 1.

## SEC filing metadata
- accession: 0001549595-26-000024
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2026-04-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000024/0001549595-26-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000024/nrix-20260408.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-26-000024
- JSON: https://secwatch.observer/filing/0001549595-26-000024.json
- Plain text: https://secwatch.observer/filing/0001549595-26-000024.txt

## Key facts
- Earnings Releases
  Nurix Therapeutics, Inc. reported the fiscal quarter ended February 28, 2026 results: revenue $6.3 million.
  - Period: the fiscal quarter ended February 28, 2026
  - Revenue: $6.3 million
  - Result: reported results
  source text: Revenue for the three months ended February 28, 2026, was $6.3 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000024/0001549595-26-000024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.